source: pixabay.com

Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS

Post author:Rose Duesterwald
Post published:November 27, 2020
Post category:Amyotrophic Lateral Sclerosis Amyotrophic lateral sclerosis type 6 Rare Disease

According to a report in BioPharma Dive, Brainstorm Therapeutics, a New York biotechnology company, said that while its NurOwn therapy for amyotrophic lateral sclerosis (ALS) appeared to have a…

Get Involved

Ready to get involved with Patient Worthy? Share your authentic story with others. Raise awareness and inspire change!

We believe rare disease patients are people, not a diagnosis. Through education, awareness and some humor, we help patients, caregivers and support persons by providing relevant and often inspirational news and stories.

Our goals are to share stories, cultivate strong community, provide the latest medical findings, connect people and pioneer production of patient worthy information. Help us attain these goals by telling us a little bit about yourself!

Get Involved

Brainstorm Shares the Results of its Phase 3 Study of NurOwn to Treat ALS

Metastatic Breast Cancer: Navigating Grief

Rethinking What It Means to Live With Acromegaly

The Let’s Chat CAR T One-on-One Mentor Program: Speaking with Someone Who Understands What You Are Going Through

Get Involved

Let’s Work Together!

Keep Up to Date

Learn More